Grapefruit for Health & Longevity - Quick Reference Sheet

Grapefruit for Health & Longevity

Created on 08/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A nutrient-dense citrus fruit supplying vitamin C, fiber, and potassium, with modest blood-pressure benefit and cholesterol improvement in those starting high. Effects on weight and blood sugar are small and inconsistent. The decisive issue is not benefit but its strong, days-long ability to raise or lower blood levels of many common medicines. (Full Review)

Protocol

Form & Quantity
½–1 whole fresh grapefruit
or ~200–250 mL 100% juice; whole fruit favored
Frequency
1–3× daily
as part of a varied diet
Timing
Shortly before meals
with food to reduce acidity discomfort
Time to effect
Nutrition & antioxidants
Immediate
vitamin C, fiber, potassium
Blood pressure & lipids
4–12 weeks
with consistent intake
Body weight
4–12 weeks
modest, inconsistent

Benefits

Contraindications
  • Organ transplant recipients on calcineurin inhibitors
  • CYP3A4-metabolized statins
  • Colchicine (esp. reduced kidney/liver function, Child-Pugh Class C)
  • Narrow-therapeutic-index antiarrhythmics
  • Any medication carrying a grapefruit warning
Key Interactions
  • Calcium channel blockers (felodipine, nifedipine, nisoldipine)
  • Benzodiazepines & sedatives (midazolam, triazolam, buspirone)
  • Direct oral anticoagulants (apixaban, rivaroxaban), ticagrelor
  • PDE5 inhibitors (sildenafil), carbamazepine, nilotinib
  • Reduced absorption: fexofenadine, aliskiren, levofloxacin, celiprolol
  • Dextromethorphan, CYP3A4-substrate antihistamines
  • Additive citrus: Seville oranges, pomelos, limes

Risk & Side Effects

  • High: CYP3A4-mediated drug interactions
  • Medium: OATP-mediated reduced drug absorption; phytophotodermatitis and photosensitivity
  • Low: Dental erosion; gastroesophageal reflux aggravation; kidney stone risk; cardiac rhythm effects at very high intake
  • Speculative: Melanoma and skin cancer association; hormone-sensitive cancer via estrogen metabolism

Monitoring

Marker Target Why
LDL cholesterol < 100 mg/dL (< 70 if high CV risk) Tracks any lipid-lowering effect
Triglycerides < 80 mg/dL Responsive to fiber and flavonoid effects
Blood pressure < 120/80 mmHg Primary measurable benefit in pooled trials
Fasting glucose 70–85 mg/dL Screens glycemic response
HbA1c < 5.3% Reflects 3-month average blood sugar
hs-CRP < 1.0 mg/L Gauges any anti-inflammatory effect
Serum potassium 4.0–4.5 mmol/L Relevant when combined with blood-pressure agents

Cadence: 8–12 weeks after establishing regular intake, then every 6–12 months; more frequent when combined with blood-pressure- or glucose-lowering agents.

Qualitative Assessment

  • Appetite and meal satiety
  • Energy levels and perceived exertion during daily activity
  • Digestive comfort (absence of reflux or acid-related discomfort)
  • Skin sensitivity to sunlight after handling or heavy intake